PCLO:CA:TSV-Pharmacielo Ltd (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.075

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. Its products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies. The company has strategic partnership with Benuvia Operations, LLC to produce cGMP pharmaceutical-grade CBD active pharmaceutical ingredients. PharmaCielo Ltd. is headquartered in Toronto, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-16 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

N/A

USD 0.13B
LOVE:CA Cannara Biotech Inc

N/A

USD 0.07B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.06B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.06B
LSL:CA LSL Pharma Group Inc.

N/A

USD 0.05B
HASH:CA Simply Solventless Concentrate..

N/A

USD 0.05B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

N/A

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

N/A

USD 9.76M

ETFs Containing PCLO:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.33% 28% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.33% 28% F 14% F
Trailing 12 Months  
Capital Gain -57.14% 28% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.14% 28% F 16% F
Trailing 5 Years  
Capital Gain -97.60% 11% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.60% 11% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -19.47% 32% F 19% F
Dividend Return -19.47% 32% F 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.60% 37% F 41% F
Risk Adjusted Return -28.81% 42% F 34% F
Market Capitalization 0.02B 60% D- 64% D

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector